I-MED Pharma Partners With Quidel to Introduce I-Lid ’N Lash, I-Relief, and SMTube to the US Market

I-MED Pharma, a company specializing in dry eye diagnosis and management, announced the signing of an exclusive distribution agreement with Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays, and molecular diagnostic systems, for I-MED Pharma’s I-Lid ’N Lash product line, the I-Relief Hot & Cold Therapy Eye Mask with ThermaBeads and the SMTube.

Daniel Hofmann, President of I-MED Pharma stated, “This is the start to a very promising partnership with a company that shares our drive and commitment to improving the ocular health of patients globally. We are confident that this alliance will lead to many further collaborations in the future.”

Quidel provides InflammaDry and AdenoPlus Eye Health diagnostic assays, which are rapid, lateral-flow based, point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. InflammaDry is Quidel’s diagnostic test that detects elevated levels of MMP-9, a key inflammatory marker for dry eye syndrome. AdenoPlus is a test on market today that differentiates between a viral and bacterial infection of acute conjunctivitis (pink eye). Both products utilize innovative patented technology, are CE marked, FDA-cleared, CLIA-waived, and complement Quidel’s existing rapid diagnostic testing solutions.

“We are pleased to partner with I-MED Pharma in providing ocular patients and health care providers with test-and-treat solutions at the point of care,” said Rick Graham, Senior Director, Business Development of Quidel. “We look forward to growing the eye health business in the future through further I-MED Pharma product introductions as well as added diagnostic testing opportunities.”